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Selecting Patients with Extensive-Stage Small Cell Lung
Cancer for Prophylactic Cranial Irradiation by Predicting
Brain Metastases
Jeffrey N. Greenspoon, MD,* William K. Evans, MD, FRCPC,*† Wenjie Cai, MSc,†
and James R. Wright, MD, FRCPC*†
Introduction: Prophylactic cranial irradiation has recently been
reported to improve overall survival and quality of life in patients
with extensive-stage small cell lung cancer. The generalizability of
this treatment to an unselected population with extensive-stage small
cell lung cancer is not clear, as the incidence of brain metastases is
variably reported in the literature, ranging from 25 to 60%.
Methods: We completed a retrospective review of 130 consecutive
patients with extensive-stage small cell lung cancer seen in consul-
tation between January 1, 2004, and December 31, 2006. Our
primary objective was to determine the incidence of brain metasta-
ses and to establish significant factors that were predictive of
developing brain metastases, using both univariate and multivariate
regression analysis.
Results: The median patient age was 68.0 years, and the median
survival time was 25.6 weeks. The majority of patients (84.9%)
received systemic therapy. Twenty-nine patients (22.3%) presented
with brain metastases while an additional 21 patients (20.8%)
developed brain metastases over their lifetime. Response to chemo-
therapy was a predictor of brain metastases using univariate (odds
ratio [OR] 5.28, p  0.03) and multivariate analysis (OR 5.49, p 
0.04). Weight loss more than 5 kg predicted for freedom from the
development of brain metastases using univariate (OR 0.20, p 
0.01) and multivariate analysis (OR 0.69, p  0.03).
Conclusions: 20.8% of patients developed brain metastases after
their initial presentation. This incidence is lower than that previously
reported and may suggest that prophylactic cranial irradiation should
be targeted to patients at highest risk. Response to chemotherapy and
less than 5 kg baseline weight loss were independent predictors of
future brain metastases.
Key Words: Small cell lung cancer, Extensive stage, Brain metas-
tases, Prophylactic cranial irradiation.
(J Thorac Oncol. 2011;6: 808–812)
Small cell lung cancer (SCLC) represents approximately14% of all primary bronchogenic cancers, and more than
70% of these patients present with extensive-stage disease.1,2
Extensive-stage SCLC (ESCLC) is historically defined as an
extent of disease that is not encompassable within a reason-
able radiation portal.2 This typically includes clinical situa-
tions such as the presence of a malignant pleural effusion,
enlarged contralateral supraclavicular nodes, or distant met-
astatic disease. The treatment of ESCLC consists of four to
six cycles of cisplatin-containing chemotherapy.3–5 Initial
response rates to chemotherapy are in the range of 60 to
70%1,2; however, the median survival of this disease is
only 9 months.1,2 In contrast, patients with limited-stage
disease, which is confined to the thorax and which can be
encompassed within a single radiation portal, typically
receive thoracic irradiation along with chemotherapy. The
median survival of limited-stage SCLC is approximately
18 months.1,2
One of the challenges to improving disease control is
the fact that the central nervous system is a recognized
sanctuary site in SCLC.1,6 Historical studies of the natural
history of SCLC have demonstrated an incidence of brain
metastases of up to 58% at 24 months.6 Studies have also
shown a decreased incidence of symptomatic brain metasta-
ses when prophylactic cranial irradiation (PCI) is pre-
scribed.4–12 The question then becomes how to select appro-
priate patients for this prophylactic intervention. Studies have
demonstrated low quality of life and a median survival of
only 4 to 6 months after the development of symptomatic
brain metastases.7–11 For patients with limited-stage disease,
two meta-analyses4,5 have demonstrated a decrease in the
incidence of symptomatic brain metastases and an improve-
ment in survival for those who receive PCI in the setting of
a complete response (CR) to combined modality therapy
consisting of chemotherapy and thoracic radiation therapy.
PCI is a standard treatment recommendation for such patients
with a good performance status.
For patients with ESCLC who achieve a CR to chemo-
therapy, the 2-year risk of brain metastasis is reported to be as
high as 50 to 60%.4 Given the established benefit of PCI in
the setting of limited stage disease, Slotman et al. hypothe-
sized a similar benefit for patients with ESCLC. Recently, the
results of the European Organisation for Research and Treat-
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ment of Cancer (EORTC) randomized clinical trial (RCT),
which evaluated the role of PCI in the setting of ESCLC at
presentation, have been published.12 Two hundred eighty-six
ESCLC patients without evidence of brain metastases, with
an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status13 of 0 to 2, and who demonstrated any response
to chemotherapy were randomized to PCI or no PCI. A
response to chemotherapy was pragmatically defined as any
response judged by the local investigator using each center’s
usual criteria. No specific criteria for treatment response were
defined in the study protocol. Patients received a dose of
radiation dependent on the institutional standard, and this
included 20 Gy in 5 or 8 fractions, 24 Gy in 12 fractions, 25
Gy in 10 fractions, 30 Gy in 10 fractions, and 30 Gy in 12
fractions, all prescribed using lateral fields to the midline.
Patients were assessed routinely in follow-up with a checklist
of key symptoms of brain metastases. If there was any
clinical suspicion of a brain metastasis, a contrast-enhanced
computed tomography (CT) or magnetic resonance imaging
(MRI) was performed. The 1-year risk of symptomatic brain
metastases was 14.6% in the PCI group and 40.4% in the
control group. PCI was associated with an increase in median
disease-free survival from 12 to 14.7 weeks and median
overall survival from 21.6 to 26.8 weeks.
Given the reported risk of 40.4% for developing brain
metastases in the standard arm of this trial,12 we wished to
evaluate the generalizability of the study findings to an
unselected consecutive patient population at our institution,
the Juravinski Cancer Centre (JCC). The JCC at Hamilton
Health Sciences is a large tertiary care center in the province
of Ontario. It is the sole provider of radiation treatment for a
catchment area of approximately 1.2 million people. We
wished to further explore the risk factors for the development
of symptomatic brain metastasis. Our primary objective was
to determine the modern incidence of symptomatic brain
metastases development in patients with ESCLC. Secondary
objectives were to establish whether any patient or treatment
factors were predictive of developing brain metastases. The
goal of our retrospective review was to determine whether
there were predictive factors that would enable us to identify
a subset of the ESCLC population at similar risk of symp-
tomatic brain metastases, as compared with the standard arm
of the EORTC trial that should receive prophylactic radiation
treatment.
METHODS
Once approval from our local research ethics board was
obtained, a retrospective chart review of a consecutive cohort
of patients with ESCLC was performed. All patients with an
initial consultation at the JCC between January 1, 2004, and
December 31, 2006, were reviewed. ESCLC was defined as
those patients with disease outside of one hemithorax, includ-
ing contralateral supraclavicular nodes, bone metastases, liver
metastases, brain metastases, adrenal metastases, lung metas-
tases, or a malignant pleural effusion. ESCLC also included
patients with extensive local disease that was not encompass-
able in a reasonable radiation portal. This judgment was
determined by the primary radiation oncologist. This could
include extensive disease in one lung or a lower lobe tumor
with ipsilateral supraclavicular nodal metastases. Perfor-
mance status was extracted by the chart reviewer using the
ECOG performance status 0 to 5 criteria,13 and if not noted
explicitly stated in the physician’s clinical notes, it was
extracted from the nurses chemotherapy flow sheets. Other
baseline factors extracted included age, gender, baseline
weight loss, and the date of the initial consultation. It was
assumed that all staging investigations would be completed
within 3 months of the initial date of consultation and were
used to determine the initial extent of the disease. CT, MRI,
bone scan, or ultrasound examinations performed within 3
months of the initial medical oncology consultation were
considered initial staging investigations. Patients were con-
sidered to have presented with brain metastases if these initial
scans were positive. These patients were included in the study
but were excluded from the analysis of factors involved in the
development of symptomatic brain metastases after initial
workup. The response to treatment was determined from
imaging tests requested by the treating oncologist and the
interpretation of the reporting radiologist. Clinical response
was determined by changes in the patient’s reported ECOG
performance status over the course of treatment with chemo-
therapy. Whenever possible, a documented change in ECOG
performance status was extracted from the clinical notes,
otherwise the reviewer assessed clinical improvement in
performance status from the dictated notes and assigned a
performance status to the patient at the end of first-line
therapy. The development of symptomatic brain metastases
had to be established by either a contrast-enhanced CT or
MRI performed after the initial staging window. Significant
patient- and treatment-related factors that were predictive of
developing brain metastases were determined using both
univariate and multivariate logistic regression analysis.
RESULTS
There were 130 patients included in our analysis. The
median age of the patients reviewed was 68 years. There were
66 males (50.8%) and 64 females (49.2%). The median
weight loss reported before initial consultation was 4.5 kg. In
our cohort, the median survival time was 25.6 weeks or 6.4
months, with a median time to the development of brain
metastases of 23.5 weeks or 5.9 months (Table 1).
Initial central nervous system staging (CT or MRI) was
performed in 119 (91.5%) patients. These staging investiga-
tions found 29 patients (22.3% of all patients with ESCLC) to
have underlying symptomatic or asymptomatic brain metas-
tases. Upfront palliative whole brain radiation therapy
TABLE 1. Descriptive Analysis
Patient Characteristic N Mean (SD) (Median) (Min, Max)
Age 130 66.8 (9.2) (68.0) (42.5, 84.8)
Weight loss (kg) 130 5.6 (6.7) (4.5) (0.0, 29.5)
Survival time (wk) 130 31.2 (25.8) (25.6) (1.0, 142.7)
Brain metastasis
subsequent time
130 29.3 (24.9) (23.5) (1.0, 142.7)
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(WBRT) was prescribed to 28 of these patients. The greatest
single site of metastatic disease at presentation was bone,
which was present in 57 (43.9%) of patients (Table 2). The
majority of patients, 111 (85.4%), received first-line chemo-
therapy, usually consisting of cisplatin and etoposide. The
remaining 19 (14.6%) patients received supportive or pallia-
tive care alone. The majority of patients had some response to
first-line chemotherapy. Seventy-five patients (57.7%) had a
partial response of which 72 (96.0%) patients had radiologic
confirmatory evidence on follow-up imaging. Fifty-five pa-
tients (73.3%) had a partial clinical response as documented
by improvement in performance status and/or functional
ability after first-line chemotherapy. After first-line chemo-
therapy, 100 patients had an ECOG performance status of 0
to 2 (77%). Only 2 (1.5%) patients had a CR to first-line
therapy, while 30 patients (23.1%) either had no response or
disease progression while receiving treatment. There was no
documentation of response to therapy in 23 (17.7%) patients
(Table 3).
Symptomatic brain metastases developed in 21 patients
subsequent to initial consultation. Excluding the 29 patients
who presented with brain metastases at the time of initial
presentation, 21 patients represent 20.8% of the remaining
cohort of 101 patients (Table 4). Univariate analysis using
logistic regression was performed on this cohort to determine
whether any factors were predictive for the development of
future brain metastases. An imaging and/or clinical response
to chemotherapy was found to be a positive predictor of
future brain metastasis with an odds ratio (OR) of 5.28 (p 
0.03). Weight loss more than 5 kg was a negative predictor of
future brain metastases with an OR of 0.20 (p  0.01). Other
factors including ECOG status, bone metastases, liver metas-
tases, and adrenal metastases were not significant (Table 5).
Multivariate logistic regression showed chemotherapy re-
sponse OR 5.49 (p  0.04) and weight loss OR 0.69 (p 
TABLE 2. Baseline Characteristics
Patient Characteristic n Frequency (%)
Gender 130
M 66 (50.8)
F 64 (49.2)
Staging investigations 130
Bone scan 106 (81.5)
CT head 60 (46.2)
MRI head 59 (45.4)
US/CT abdomen 124 (95.4)
LFTs 125 (96.2)
Bone marrow 1 (0.8)
Weight loss 5 kg 130 53 (40.8)
Clinical extent 130
Pleural effusion 30 (23.1)
Ipsilateral SCV node 21 (16.2)
Contralateral SCV node 9 (6.9)
Bone metastasis 57 (43.9)
Liver metastasis 45 (34.6)
Lung metastasis 27 (20.8)
Adrenal metastasis 26 (20.0)
Brain metastasis 29 (22.3)
Initial WBRT 29 28 (96.6)
CT, computed tomography; MRI, magnetic resonance imaging; US, ultrasound;
LFT, liver function test; SCV, supraclavicular; WBRT, whole brain radiation therapy.
TABLE 3. Treatment and Response
Patient Characteristic N Frequency (%)
Initial chemotherapy 130
Cisplatin 62 (47.7)
Etoposide 84 (64.6)
Oral etoposide 24 (18.5)
None 19 (14.6)
ECOG performance status 130
0 3 (2.3)
1 49 (37.7)
2 48 (36.9)
3 21 (16.2)
4 9 (6.9)
Response 130
Partial 75 (57.7)
Imaging response 75 72 (96.0)
Clinical response 75 55 (73.3)
Complete 2 (1.5)
No response 14 (10.8)
Progression 16 (12.3)
Not commented 23 (17.7)
Deceased 130 124 (95.4)
ECOG, Eastern Cooperative Oncology Group.
TABLE 4. Symptomatic Brain Metastases
Patient Characteristic n Frequency (%)
Brain metastasis at presentation 29 29/130 (22.3)
No brain metastasis at presentation 101 101/130 (77.7)
Developed symptomatic brain metastasis 21 21/101 (20.8)
Confirmed by CT 12 12/21 (57.1)
Confirmed by MRI 12 12/21 (57.1)
Received WBRT 18 18/21 (85.7)
CT, computed tomography; MRI, magnetic resonance imaging; WBRT, whole
brain radiation therapy.
TABLE 5. Univariate Logistic Regression for the 101
Patients in Table 4
Variable Odds Ratio (95% CI) p
ECOG 0.97 (0.57, 1.65) 0.91
ECOG (0–2 vs. 3–4) 0.39 (0.08, 1.86) 0.24
Weight loss (kg) 0.90 (0.80, 1.01) 0.07
Weight loss 5 kg 0.20 (0.05, 0.73) 0.01a
Bone metastasis 0.68 (0.24, 1.94) 0.47
Liver metastasis 0.80 (0.27, 2.34) 0.68
Adrenal metastasis 0.84 (0.22, 3.24) 0.80
Chemotherapy response 5.28 (1.14, 24.49) 0.03a
a Statistically significant (  0.05, two tailed).
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group.
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0.03) to be independent predictors of future brain metastasis
(Table 6). Applying the same inclusion criteria as the RCT
protocol by Slotman et al.12 (ECOG 0–2 and a response to
chemotherapy), 16 patients of a cohort of 64 patients (25.0%)
developed symptomatic brain metastasis. Of the 60 patients
in our highest-risk group (weight loss 5 kg and a response
to chemotherapy), 18 patients (30.0%) developed a symptom-
atic brain metastasis.
DISCUSSION
In our series, 20.1% of neurologically negative patients
on initial staging CT and/or MRI developed a symptomatic
brain metastasis over the course of their illness. This is lower
than the reported 1-year incidence rate of 40.4% in the recent
EORTC RCT.12 At our center, the median survival time was
25.6 weeks for patients with ESCLC. This is comparable to
the 26.8-week median survival in the PCI arm and longer
than the 21.6 weeks in the standard arm of the recent RCT.12
Applying PCI to all patients in the ESCLC group eligible for
the EORTC study could therefore be questioned. We have,
however, identified a higher-risk cohort, based on both sys-
temic therapy response and lack of initial weight loss that has
a 30.0% risk of developing symptomatic brain metastasis.
Brain metastases have a negative social impact on
patients and care givers9 and impair a patient’s quality of
life.7,8 PCI has proven benefit in terms of decreasing the
incidence of symptomatic brain metastases in the ESCLC
population6,12 without short-term impairment of cognitive
function.14,15 The goal of PCI in our population would there-
fore be to prevent symptoms from developing in a high-risk
group therefore improving or sustaining quality of life. Our
review was performed to determine how closely our patient
cohort matched the outcomes reported for the standard arm of
the recent RCT,12 and if different to determine whether we
could more appropriately define a group of patients with a
similar risk for developing symptomatic brain metastases.
PCI using conventional fractionation does not appear to
impact short-term cognitive function,12,14–17 making it a rea-
sonable treatment recommendation in neurologically asymp-
tomatic patients with ESCLC, a good performance status,
response to upfront chemotherapy, and minimal initial weight
loss. PCI does cause fatigue, hair loss, appetite loss, nausea,
and vomiting12 and should therefore be offered to patients
most likely to receive benefit.
Prophylactic palliative treatment is not the traditional
treatment approach of radiation oncology. It is important that
we closely define a population of patients who will likely
benefit from PCI. Despite its tolerability, PCI requires pa-
tients with ESCLC to make visits while feeling well to a
cancer center to receive a prophylactic palliative treatment
that will likely only benefit 20 to 30% of patients and cause
acute side effects in the majority.12 This study has helped
define two key risk factors (a response to first-line chemo-
therapy and weight loss 5 kg) that predict for the future
development of a symptomatic brain metastasis. In our un-
selected population, with a similar median survival to patients
in the experimental arm of the EORTC RCT, it is clear that
the risk of developing clinically significant brain metastases
is lower than that reported in the recently published clinical
trial.12 This may be due to the general poor prognosis of
patients with ESCLC and the appropriate rapid institution
of palliative care and individualized patient treatment. Many
patients in clinical trials are not representative of the larger
population from which they have been sampled and typic-
ally are younger, with less disease burden and better perfor-
mance status.18 The patients in our cohort had an older
median age of 68.0 years compared with the median age of
62.5 years in the EORTC RCT.12 Our cohort also contained
patients with an ECOG status of 3 and 4 and patients with no
response or progressive disease, after first-line chemotherapy.
Even with similar criteria, our patient population had a lower
risk of developing brain metastasis. Ironically, being younger
with less disease burden likely increases the risk of living
long enough to develop brain metastases in ESCLC.
In a population of patients with a median survival of 9
months, we would not routinely offer intensive clinical fol-
low-up at our cancer center after the completion of upfront
treatment. We typically empower patients, families, and com-
munity palliative physicians to seek palliative symptomatic
treatment if they wish. The standard follow-up interval would
be visits every 2 to 3 months or when symptoms arise, but
this decision usually involves weighing the benefits of treat-
ment verses travel time, acute side effects, and time away
from family and loved ones. It currently appears reasonable
to discuss PCI as a prophylactic palliative treatment in pa-
tients with the diagnosis of ESCLC who are at high risk for
the development of symptomatic brain metastases. When
combining this review with the results of the recent EORTC
randomized trail,12 a reasonable way of selecting a high-risk
population for this discussion can be defined. This population
would be high-functioning patients with an ECOG perfor-
mance status 0 to 2 who have had a good partial response to
upfront chemotherapy treatment and have not had significant
weight loss (5 kg) leading up to their initial oncology
consultation. The addition of significant weight loss (5 kg)
to the inclusion criteria of the EORTC trial (ECOG perfor-
mance status 0–2 and response to chemotherapy12) defines a
population has the least aggressive disease and will likely live
long enough to be at risk for developing symptomatic brain
TABLE 6. Multivariate Logistic Regression Analysis for the
101 Patients in Table 4
Variable
Estimated Coefficient
(95% CI)
Odds Ratio
(95% CI) p
Model 1
(2logL 
80.8, AIC 
90.8)
Constant 2.28 (4.32, 0.24)
Chemotherapy
response
1.70 (0.07, 3.33) 5.49 (1.08, 27.91) 0.04a
Weight loss (kg) 0.38 (0.72, 0.03) 0.69 (0.49, 0.97) 0.03a
a Statistically significant (  0.05, two tailed).
CI, confidence interval.
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metastases before systemic relapse and progression. This
population would likely derive the greatest benefit from PCI,
but this conclusion cannot be drawn without definitive ran-
domized prospective trials assessing this more narrowly de-
fined patient population.
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